Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Aldeyra Therapeutics,Inc. (NASDAQ: ALDX).

Full DD Report for ALDX

You must become a subscriber to view this report.


Recent News from (NASDAQ: ALDX)

Consolidated Research: 2018 Summary Expectations for PDF Solutions, MYOS RENS Technology, Aldeyra Therapeutics, The Ensign Group, Everi, and Ardelyx - Fundamental Analysis, Key Performance Indications
NEW YORK, Aug. 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PDF Solutions, Inc. (NASDAQ:PDFS), MYOS RENS Technology Inc. (NASDAQ:MYOS...
Source: GlobeNewswire
Date: August, 17 2018 08:20
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q2 2018 Results - Earnings Call Transcript
Aldeyra Therapeutics, Inc. (ALDX) Q2 2018 Earnings Conference Call August 09, 2018, 08:00 ET Executives Joshua Reed - CFO Todd Brady - CEO, President & Director Analysts Neil Carnahan - Stifel, Nicolaus & Company Elemer Piros - Cantor Fitzgerald & Co. I-Eh Je...
Source: SeekingAlpha
Date: August, 09 2018 13:50
Aldeyra Therapeutics Announces Second Quarter 2018 Financial Results and Provides Corporate Update
LEXINGTON, Mass. , Aug. 9, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced financial results f...
Source: PR Newswire
Date: August, 09 2018 07:30
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second Quarter 2018 Financial Results and Corporate Update
LEXINGTON, Mass. , Aug. 2, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, will hold a conference call on Thursday, August ...
Source: PR Newswire
Date: August, 02 2018 08:00
Aldeyra Therapeutics to Present at the 38th Annual Canaccord Genuity Growth Conference
LEXINGTON, Mass. , Aug. 1, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady , M.D., Ph.D...
Source: PR Newswire
Date: August, 01 2018 08:00
Aldeyra Therapeutics Appoints Joshua Reed as Chief Financial Officer
LEXINGTON, Mass. , July 31, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced the appointment of Joshua...
Source: PR Newswire
Date: July, 31 2018 08:00
Aldeyra commences late-stage study of reproxalap in rare inherited skin disorder
Enrollment is underway in a Phase 3 clinical trial evaluating Aldeyra Therapeutics' ( ALDX +0.6% ) topical dermal reproxalap for the treatment of ichthyosis (thickened, dry scaly skin) in patients with Sjögren-Larsson Syndrome (SLS). More news on: Aldeyra Therapeutics, Inc., He...
Source: SeekingAlpha
Date: July, 24 2018 09:53
Aldeyra Therapeutics Announces First Patient Enrolled in Sjögren-Larsson Syndrome Pivotal Phase 3 Clinical Trial
LEXINGTON, Mass. , July 24, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that the first patient has enro...
Source: PR Newswire
Date: July, 24 2018 08:00
Aldeyra Therapeutics Announces Last Patient Dosed in Dry Eye Disease Phase 2b Clinical Trial
LEXINGTON, Mass. , July 12, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to the development of next-generation medicines to improve the lives of patients with immune-mediated diseases, announced that the last patient has complet...
Source: PR Newswire
Date: July, 12 2018 08:00
Aldeyra Therapeutics Announces Development Programs at 2018 Research Day
LEXINGTON, Mass. , June 26, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to the development of next-generation medicines to improve the lives of patients with immune-mediated diseases, announced product development programs in s...
Source: PR Newswire
Date: June, 26 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-087.807.907.9757.77546,573
2018-05-178.909.1759.2758.8674219,956
2017-06-204.504.254.504.2545,754
2017-06-194.454.454.554.3595,816
2017-06-164.104.304.454.1079,648

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1113,31227,96347.6058Short
2018-12-1027,14476,33535.5590Short
2018-12-0717,80235,64449.9439Short
2018-12-0625,88770,52936.7041Short
2018-12-0452,973133,14239.7868Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ALDX.


About Aldeyra Therapeutics,Inc. (NASDAQ: ALDX)

Logo for Aldeyra Therapeutics,Inc. (NASDAQ: ALDX)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: ALDX)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 15 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 15 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 25 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 25 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 29 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 29 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 29 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 27 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 13 2018

       

       


      Daily Technical Chart for (NASDAQ: ALDX)

      Daily Technical Chart for (NASDAQ: ALDX)


      Stay tuned for daily updates and more on (NASDAQ: ALDX)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: ALDX)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ALDX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ALDX and does not buy, sell, or trade any shares of ALDX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/